Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 443, 153-154 (14 September 2006) | doi:10.1038/443153a; Published online 13 September 2006
Open Innovation Challenges
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
- More Challenges
- Powered by:
nature jobs
Postdoctoral Fellow (Genetics / Genomics of Brain Tumors)
- M.D. Anderson Cancer Center
- Houston, Texas, USA
Faculty Position - Center for Viral Oncology
- University of Kansas Medical Center
- Kansas City, KS
Cancer biology: Can less be more for p53?
Anton Berns1
Abstract
The tumour-suppressor protein p53 is often mutated in cancer. But it seems that p53 deficiency is not all bad, and inhibiting this protein might mitigate toxic side effects of chemotherapy and radiotherapy.
The p53 protein gained its reputation as the 'guardian of the genome' because it mediates the cell's response to certain types of injury, relaying signals from both the DNA-damage response pathway and the oncogenic (tumour-promoting) stress pathway. Defects in these pathways are associated with a predisposition to cancer, and because they converge on p53, it has always been assumed that they act primarily through this crucial protein.
- Anton Berns is in the Division of Molecular Genetics and Centre of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Email: a.berns@nki.nl
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige miceLeukemia Original Article
